Redeye endorses that CLS has received FDA clearance for its MR-guided laser ablation system in neurosurgery. We believe this is an essential milestone for the company and crucial for its commercialization in the US. We make no valuation changes on the back of today's news, owing to our valuation already taking height for a launch in the US. However, during the fall, we will provide an update where we review the case and our forecasts.